成人髓母细胞瘤的99mTc-HYNIC-[D-Phe1,Tyr3-奥曲肽] SPECT/CT显像
本文报道一例67岁男性小脑髓母细胞瘤术后、化疗及放疗后残留病灶,采用99mTc-HYNIC-[D-Phe1,Tyr3-奥曲肽] SPECT/CT进行生长抑素受体显像,用于分期及评估生长抑素类似物或肽受体放射性核素治疗的可行性。成人髓母细胞瘤发病率约0.6–1例/百万,占成人脑肿瘤不足1%,多位于后颅窝。
要点
- 成人髓母细胞瘤极罕见,发病率约0.6–1例/百万,占成人脑肿瘤不足1%。
- 99mTc-HYNIC-[D-Phe1,Tyr3-奥曲肽] SPECT/CT可用于生长抑素受体显像。
- 该显像用于分期及评估生长抑素类似物或肽受体放射性核素治疗可能性。
核心结论
- 生长抑素受体显像可用于成人髓母细胞瘤残留病灶的分期及评估生长抑素类似物或肽受体放射性核素治疗的可能性。
研究设计与样本
- 个案报道:一例67岁男性小脑髓母细胞瘤患者,术后、化疗及放疗后存在残留病灶,行99mTc-HYNIC-[D-Phe1,Tyr3-奥曲肽] SPECT/CT生长抑素受体显像。
主要发现
- 成人髓母细胞瘤发病率约0.6–1例/百万,占成人脑肿瘤不足1%,最常位于后颅窝。
- 该例为67岁男性小脑髓母细胞瘤,术后、化疗及放疗后仍有残留病灶。
临床怎么用
- 对成人髓母细胞瘤残留病灶,可考虑行生长抑素受体显像以辅助分期并评估生长抑素类似物或肽受体放射性核素治疗的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although medulloblastoma constitutes the second most common malignant brain tumor in children, it encountered very rarely in adults. The incidence of adult medulloblastoma is approximately 0.6 to 1 case per million. It accounts for less than 1% of adult brain tumors and is located most commonly at the posterior cranial fossa. We present an extremely rare case of a 67-year-old man with cerebellar medulloblastoma with residual disease after surgery, chemotherapy, and radiation therapy, depicted with Tc-HYNIC-[D-Phe, Tyr-Octreotide] SPECT/CT. Somatostatin receptor scintigraphy was performed for staging and for the possibility of treatment with somatostatin analogs or peptide radionuclide therapy.
引用
- Spyridonidis T, Papathanasiou N, Spiliotopoulou M, et al. Adult Medulloblastoma Depicted With 99mTc-HYNIC-[D-Phe1, Tyr3-Octreotide] SPECT/CT. Clin Nucl Med. 2020. PMID: 33086272. doi:10.1097/RLU.0000000000003341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。